amifampridine has been researched along with Cerebellar Diseases in 2 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
Cerebellar Diseases: Diseases that affect the structure or function of the cerebellum. Cardinal manifestations of cerebellar dysfunction include dysmetria, GAIT ATAXIA, and MUSCLE HYPOTONIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gill, AJ | 1 |
| Gandhy, S | 1 |
| Lancaster, E | 1 |
| Helmchen, C | 1 |
| Gottschalk, S | 1 |
| Sander, T | 1 |
| Trillenberg, P | 1 |
| Rambold, H | 1 |
| Sprenger, A | 1 |
2 other studies available for amifampridine and Cerebellar Diseases
| Article | Year |
|---|---|
Nivolumab-associated Lambert-Eaton myasthenic syndrome and cerebellar dysfunction in a patient with a neuroendocrine tumor.
Topics: Amifampridine; Antineoplastic Combined Chemotherapy Protocols; Calcium Channels, P-Type; Calcium Cha | 2021 |
Beneficial effects of 3,4-diaminopyridine on positioning downbeat nystagmus in a circumscribed uvulo-nodular lesion.
Topics: 4-Aminopyridine; Adult; Amifampridine; Cerebellar Diseases; Humans; Magnetic Resonance Imaging; Male | 2007 |